The future of prescription drug costs in the United States may hinge on ongoing negotiations between the Federal Trade Commission (FTC) and two of the nation’s largest pharmacy benefit managers (PBMs): Optum Rx and Caremark. Discussions are reportedly progressing, raising the possibility of settlements similar to the one recently reached with Express Scripts, Inc. (ESI), and potentially reshaping how Americans access and pay for essential medications. The core issue revolves around allegations that anticompetitive practices by these PBMs have artificially inflated the price of drugs, particularly insulin, impacting millions of patients.
The FTC’s scrutiny of PBMs stems from concerns about a complex system of rebates and negotiating tactics that, rather than lowering costs, may incentivize the selection of higher-priced drugs. These practices, the FTC argues, lack transparency and ultimately burden consumers with inflated out-of-pocket expenses. The agency’s actions signal a growing effort to address the rising cost of healthcare and ensure fair pricing for prescription medications. This case is particularly significant given the widespread reliance on insulin for individuals with diabetes and the potentially life-threatening consequences of unaffordable access.
The current situation builds upon a landmark settlement secured by the FTC with Express Scripts on February 4, 2026. This agreement, expected to drive down patient costs for drugs like insulin by up to $7 billion over the next decade, requires ESI to implement fundamental changes to its business practices. These reforms aim to increase transparency and deliver millions of dollars in new revenue to community pharmacies annually. The settlement with Express Scripts has undoubtedly set pressure on Optum Rx and Caremark to consider similar resolutions to avoid prolonged and potentially damaging litigation.
FTC and PBMs in Settlement Talks
According to a court filing this week, the FTC is making “significant progress” in settlement talks with both Optum Rx, owned by UnitedHealth Group, and Caremark, a subsidiary of CVS Health. The case had been stayed until late March to allow these negotiations to continue, as outlined in a commission order issued on March 3, 2026. Both UnitedHealth and CVS Health have declined to provide specific details regarding the ongoing discussions. Although, a spokesperson for Caremark stated the company is “engaged in great-faith negotiations with the FTC, aimed at avoiding prolonged litigation and allowing CVS Caremark to keep doing what it does best: make prescription drugs more affordable in the US.”
The FTC initially filed suit against Express Scripts, Optum Rx, and Caremark in September 2024, alleging that their negotiating practices with drug manufacturers prioritized higher-cost drugs, ultimately driving up the price of insulin for patients. The agency’s complaint detailed how these PBMs allegedly favored drugs that offered larger rebates, even if less expensive alternatives were available. This practice, the FTC contends, undermines the principles of a competitive market and harms consumers. The lawsuit highlighted the critical role PBMs play in the pharmaceutical supply chain and the potential for abuse within that system.
The Express Scripts Settlement: A Precedent
The settlement with Express Scripts, owned by Cigna, served as a pivotal moment in the FTC’s broader investigation. The agreement largely codified reforms that Express Scripts was already implementing, and analysts suggest it is unlikely to significantly impact the company’s long-term profitability. Executives at Cigna indicated to investors that the settlement was a positive outcome, allowing the company to move forward with greater clarity. Federal regulators, however, hailed the settlement as a victory for consumers, emphasizing its potential to lower drug costs and increase transparency within the pharmaceutical supply chain.
The FTC suspended action against Express Scripts in late January 2026 to consider the proposed settlement, ultimately finalizing the deal the following month. This move signaled the agency’s willingness to negotiate and find resolutions that address its concerns without resorting to lengthy and costly litigation. The Express Scripts settlement included provisions for increased transparency in rebate negotiations and a commitment to prioritize lower-cost drug options for patients. It also established mechanisms for monitoring and enforcing compliance with the agreement’s terms.
Impact on Insulin Costs and the Pharmaceutical Landscape
The potential settlements with Optum Rx and Caremark could have far-reaching implications for the pharmaceutical industry and the millions of Americans who rely on prescription medications. Insulin, a life-sustaining drug for individuals with diabetes, has been a focal point of the FTC’s investigation due to its consistently rising prices. According to the American Diabetes Association, over 37.3 million Americans have diabetes, and many require insulin to manage their condition. The affordability of insulin is therefore a critical public health issue.
PBMs act as intermediaries between drug manufacturers, insurance companies, and pharmacies, negotiating drug prices and managing prescription drug benefits for health plans. They wield significant influence over which drugs are covered and at what cost. Critics argue that the current PBM model lacks transparency and creates incentives for prioritizing profits over patient affordability. The FTC’s lawsuit and ongoing settlement negotiations aim to address these concerns and promote a more equitable and transparent system.
What’s at Stake for Patients?
If settlements are reached with Optum Rx and Caremark, patients could potentially benefit from lower out-of-pocket costs for prescription drugs, particularly insulin. Increased transparency in rebate negotiations could also empower patients and healthcare providers to make more informed decisions about medication choices. The settlements could encourage greater competition among PBMs, leading to further cost reductions and improved access to affordable medications. However, the full extent of the impact will depend on the specific terms of any agreements reached.
The FTC’s actions reflect a broader trend of increased regulatory scrutiny of the pharmaceutical industry and a growing demand for greater affordability and transparency in healthcare. The agency’s pursuit of settlements with these major PBMs underscores its commitment to protecting consumers and ensuring fair competition in the marketplace. The outcome of these negotiations will likely set a precedent for future regulatory actions and shape the future of prescription drug pricing in the United States.
Next Steps and Ongoing Monitoring
As of March 5, 2026, settlement discussions between the FTC and Optum Rx and Caremark are ongoing, with the case currently stayed until late March to allow for continued negotiations. The FTC is expected to provide updates on the progress of these talks as they become available. The agency’s website (https://www.ftc.gov/) will serve as a primary source of information regarding the case and any future developments. Consumers and healthcare professionals are encouraged to stay informed about these negotiations and their potential impact on prescription drug costs.
The resolution of this case will be closely watched by stakeholders across the healthcare industry, including pharmaceutical manufacturers, insurance companies, pharmacies, and patient advocacy groups. The outcome could have significant implications for the future of PBMs and the overall structure of the pharmaceutical supply chain. It remains to be seen whether the settlements will lead to lasting changes that truly benefit consumers and improve access to affordable medications.
What are your thoughts on the FTC’s actions and the potential impact on prescription drug costs? Share your comments below, and please share this article with your network to help spread awareness about this important issue.
Worth a look